KVD900   Click here for help

GtoPdb Ligand ID: 11947

Compound class: Synthetic organic
Comment: KVD900 is an oral plasma kallikrein (KLKB1) inhibitor that is being developed by KalVista Pharmaceuticals as a therapeutic option that is intended for use early upon the onset of hereditary angioedema (HAE) attacks [1]. Its structure was revealed during the 'first disclosure' session at the ACS Spring 2022 meeting.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 100.27
Molecular weight 477.18
XLogP 3.43
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1nn(cc1C(=O)NCc1nccc(c1F)OC)Cc1ccc(cc1)Cn1ccccc1=O
Isomeric SMILES COc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F
InChI InChI=1S/C25H24FN5O4/c1-34-21-10-11-27-20(23(21)26)13-28-24(33)19-16-31(29-25(19)35-2)15-18-8-6-17(7-9-18)14-30-12-4-3-5-22(30)32/h3-12,16H,13-15H2,1-2H3,(H,28,33)
Classification Click here for help
Compound class Synthetic organic
IUPAC Name Click here for help
Database Links Click here for help
GtoPdb PubChem SID 461663502
Search Google for chemical match using the InChIKey QTNIRGIZAWMZRE-UHFFFAOYSA-N
Search Google for chemicals with the same backbone QTNIRGIZAWMZRE
UniChem Compound Search for chemical match using the InChIKey QTNIRGIZAWMZRE-UHFFFAOYSA-N
UniChem Connectivity Search for chemical match using the InChIKey QTNIRGIZAWMZRE-UHFFFAOYSA-N